LYPD3 and lung carcinoma: Additionally, the Ly6/PLAUR domain-containing protein 3 (LYPD3) emerged as a novel target for development of a lung cancer targeted therapy, which could be co-developed with a companion imaging agent for the personalized treatment of lung cancer.